Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) display type 2 inflammatory pathophysiology. Comorbid NSAID-ERD is associated with higher morbidity and polyp recurrence rates. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13, key and central drivers of type 2 inflammation. We report the effect of dupilumab on biomarkers of type 2 inflammation in patients with CRSwNP and comorbid NSAID-ERD in the SINUS-52 study (NCT02898454).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
